In a significant advancement in weight-loss treatment, the U.S. Food and Drug Administration (FDA) has granted approval for Foundayo, a new oral GLP-1 medication developed by Eli Lilly. This marks the second approval of an oral GLP-1 drug in the United States, following the December 2025 approval of Novo Nordisk’s Wegovy. This once-daily pill is designed for adults classified as obese or those with weight-related health conditions, aiming to help them shed excess weight.
Details of the Approval
The FDA’s decision, announced on Wednesday, came just 50 days after Eli Lilly submitted its application—one of the swiftest timelines in the agency’s history for drug approval. Martin Makary, the FDA commissioner, stated, “This approval demonstrates what the FDA can achieve when we eliminate delays and prioritise fast and thorough work from the agency and industry partners.”
While the approval is a positive step, it remains uncertain whether Foundayo is safe for paediatric use. Eli Lilly emphasised that the medication should be taken in conjunction with a reduced-calorie diet and increased physical activity to maximise effectiveness.
Clinical Trial Results
In clinical trials, participants who took the highest dose of Foundayo and adhered to the treatment regimen experienced an average weight loss of 27.3 pounds (12.3 kilograms), significantly more than the 2.2 pounds (0.9 kg) lost by those taking a placebo. This substantial difference highlights the potential of Foundayo as a tool in combating obesity—a condition that poses significant health risks.
The recommended starting dosage for Foundayo is 0.8 milligrams, which can be escalated to 2.5 mg after 30 days, and then to 5.5 mg after an additional month. Higher doses up to 17.2 mg can be considered based on the patient’s response and tolerability.
Cost and Side Effects
For those without insurance, Foundayo will be priced at approximately US$149 per month. While this cost might be prohibitive for some, the potential benefits could outweigh the financial burden for individuals struggling with obesity.
However, it is essential to consider the medication’s side effects. Commonly reported adverse reactions include nausea, constipation, vomiting, and abdominal discomfort. More serious concerns have been raised, as Eli Lilly acknowledged that Foundayo may increase the risk of thyroid tumours, including cancer. Additional studies conducted this year have highlighted further risks associated with GLP-1 medications, including stomach paralysis, pancreatitis, and even sudden irreversible vision loss.
The Bigger Picture
The introduction of Foundayo into the market reflects a growing recognition of obesity as a serious health issue that requires effective solutions. With obesity rates continuing to rise, the development of new pharmacological options is crucial. However, the balance between benefits and risks must be carefully navigated, particularly in light of the concerning side effects associated with GLP-1 medications.
Why it Matters
The approval of Foundayo represents a critical advancement in the ongoing battle against obesity, a condition that affects millions globally and is linked to various serious health complications. As healthcare systems grapple with the implications of rising obesity rates, innovations like Foundayo could play a pivotal role in providing effective treatment options. However, it is essential for patients and healthcare providers to remain vigilant about potential side effects, ensuring that the pursuit of weight loss does not come at the expense of overall health and well-being. As we look to the future, it is vital that healthcare policies adapt to incorporate these new treatments while prioritising patient safety.
